Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Samsung Bioepis’ breast cancer treatment biosimilar launches in US
By Lim Jeong-yeoPublished : April 16, 2020 - 17:12
Samsung Bioepis’ breast cancer treatment Ontruzant (trastuzumab) was launched in the US via local partner Merck, Thursday.
Ontruzant references Roche’s blockbuster original Herceptin, which recorded annual global revenue of approximately 7.2 trillion won ($5.8 billion) in 2019.
The US accounts for about 45 percent of Herceptin sales.
Samsung Bioepis strategizes to sell Ontruzant at a 15 percent more affordable rate than Herceptin, as well as to offer doses of 150 milligrams and 420 milligrams to expand prescription options.
This is the second biosimilar that Samsung Bioepis has launched in the US, the biggest pharmaceuticals market in the world, following rheumatoid arthritis treatment Renflexis in 2017. Renflexis references Janssen’s Remicade (infliximab).
Merck is also responsible for Renflexis’ US sales.
Samsung Bioepis also has US commercialization approvals for its Enbrel (etanercept) biosimilar Eticovo and Humira (adalimumab) biosimilar Hadlima. Both drugs treat rheumatoid arthritis. They have yet to be launched for the US market.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Ontruzant references Roche’s blockbuster original Herceptin, which recorded annual global revenue of approximately 7.2 trillion won ($5.8 billion) in 2019.
The US accounts for about 45 percent of Herceptin sales.
Samsung Bioepis strategizes to sell Ontruzant at a 15 percent more affordable rate than Herceptin, as well as to offer doses of 150 milligrams and 420 milligrams to expand prescription options.
This is the second biosimilar that Samsung Bioepis has launched in the US, the biggest pharmaceuticals market in the world, following rheumatoid arthritis treatment Renflexis in 2017. Renflexis references Janssen’s Remicade (infliximab).
Merck is also responsible for Renflexis’ US sales.
Samsung Bioepis also has US commercialization approvals for its Enbrel (etanercept) biosimilar Eticovo and Humira (adalimumab) biosimilar Hadlima. Both drugs treat rheumatoid arthritis. They have yet to be launched for the US market.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
